You are here

Pharmaceutical Approval Update October 2009

Marvin M. Goldenberg, PhD, RPh, MS
PDF version: 
Topics include asenapine sublingual tablets (Saphris) for schizophrenia and bipolar disorder; saxagliptin (Onglyza) for obtaining glucose control in type-2 diabetes; and interferon beta-1b (Extavia) injection for patents with multiple sclerosis.